Pediatric Hyperlipidemia Guidelines

Le résumé fourni par la source

Atherosclerotic cardiovascular disease originates in childhood, and cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a major determinant of lifetime cardiovascular risk. Multiple professional societies have published guidelines for lipid screening, diagnosis, and management in pediatric populations; yet important differences exist among these recommendations. Our objective is to review and compare major pediatric dyslipidemia guidelines and identify areas of consensus, disagreement, and remaining evidence gaps. A narrative review was conducted to compare recommendations from major professional society guidelines on lipid screening, diagnostic criteria, lifestyle management, pharmacologic therapy, and management of hypertriglyceridemia. Across guidelines, there is broad agreement that lifestyle modification is first-line therapy and that statins are safe and effective for children with familial hypercholesterolemia. Key differences exist around universal screening, the age and LDL-C thresholds for statin initiation, LDL-C treatment targets, and the role of genetic testing. More recent guideline updates support earlier identification and treatment of pediatric dyslipidemia, particularly in children with familial hypercholesterolemia. Pediatric dyslipidemia guidelines are evolving toward earlier detection and more intensive management of lipid disorders in children. However, important evidence gaps remain, including limited long-term cardiovascular outcome data following childhood lipid-lowering therapy, insufficient pediatric evidence for newer lipid-lowering agents, and persistent disparities in access to screening.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.